CXCR4 and Familial prostate cancer: Of interest to future studies in sarcomas, silencing of CXCR4 axis contributions sufficed to compromise initial establishment of prostate cancers in bone microenvironment, whereas established bone tumors were sensitive only to RTK inhibitors [40].